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Characterization and Optimization of the Glucan Particle-Based
Vaccine Platform
Haibin Huang,a Gary R. Ostroff,b Chrono K. Lee,a Charles A. Specht,a Stuart M. Levitza
Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USAa; Program in Molecular Medicine, University of Massachusetts
Medical School, Worcester, Massachusetts, USAb
Glucan particles (GPs) are hollow porous Saccharomyces cerevisiae cell walls that are treated so that they are composed primar-
ily of-1,3-D-glucans. Our previous studies showed that GPs can serve as an effective vaccine platform. Here, we characterize
CD4 T-cell and antibody responses in immunized mice as a function of antigen (ovalbumin) encapsulation, antigen dose, parti-
cle numbers, time, immunization schedule, and trapping methods. Although we found that GPs served as an effective adjuvant
when admixed with free antigens for IgG1 antibody production, stronger CD4 T-cell and IgG2c antibody responses were stim-
ulated when antigens were encapsulated inside GPs, suggesting that the GP platform acts as both an adjuvant and a delivery sys-
tem. Vigorous T-cell and antibody responses were stimulated even at submicrogram antigen doses, as long as the number of GPs
was kept at 5 107 particles per immunization. One prime and one boost were sufficient to elicit robust immune responses. In
addition, strong antigen-specific antibody and T-cell responses prevailed up to 20 months following the last immunization, in-
cluding those of gamma interferon (IFN-), interleukin 17A (IL-17A), and dual IFN-/IL-17A-secreting CD4 T cells. Finally,
robust immune responses were observed using generally recognized as safe (GRAS) materials (alginate and calcium, with or
without chitosan) to trap antigens within GPs. Thus, these studies demonstrate that antigens encapsulated into GPs make an
effective vaccine platform that combines adjuvanticity and antigen delivery to elicit strong durable immune responses at rela-
tively low antigen doses using translationally relevant formulations.
The development of vaccines is one of the greatest achievementsin the history of medicine. Vaccines can be classified as live
attenuated and inactivated. While live vaccines typically generate
longer lasting immunity, they tend to have a poorer safety profile
and are contraindicated in immunocompromised persons.
Among the inactivated vaccines, subunit vaccines have the theo-
retical advantage of being safer, but the antigens used in them
generally have little to no intrinsic antigenicity and therefore re-
quire administration with adjuvants (1).
The most commonly used adjuvant in clinical use, aluminum
salts (alum), generally elicits strong antibody responses to coad-
ministered antigens.However, there is a critical need for adjuvants
that stimulate protective T-cell responses against those diseases
for which antibodies alone are not protective. To this end, we have
developed a glucan particle (GP)-based vaccine platform (2). GPs
are derived from Saccharomyces cerevisiae and predominantly
consist of -1,3-D-glucans (3). -1,3-D-Glucans are fungal cell
wall pathogen-associated molecular patterns (PAMPs) (4, 5) that
are recognized by host phagocytic -1,3-D-glucan receptors, in-
cluding Dectin-1 (6), CR3 (7), and scavenger receptors (8–10).
-1,3-D-Glucans also activate the alternative pathway of comple-
ment, with deposition of C3 fragments that are recognized by
complement receptors (11).
We have shown that mice immunized three times with GPs
containing ovalbumin complexed with yeast RNA develop robust
antigen-specific antibody and Th1- and Th17-biased CD4T-cell
responses (2). The goals of the present study were to address un-
answered issues that are relevant to the development of GP-based
vaccines for eventual use in humans. The importance of GPs as an
adjuvant independent of its antigen delivery properties was deter-
mined by comparing immune outcomes when antigens were sim-
ply mixed with GPs versus being encapsulated inside GPs. Vac-
cines that are dose sparing and elicit rapid immune responsesmay
be lifesaving in urgent situations, such as during influenza pan-
demics or in response to bioterrorism threats. Therefore, we ex-
amined the antibody and T-cell responses that occur when reduc-
ing the (i) amount of antigen loaded into GPs, (ii) number of GPs
per immunization, and (iii) number of boosters. Long-term im-
munity is desirable for most vaccines but has been difficult to
achieve with inactivated vaccines. Here, we studied the durability
of immune responses up to 20months postimmunization. Finally,
we addressed issues of safety in and translation to human use by
examining the immunogenicity of GPs formulated with antigen-
entrapping materials (alginate, calcium, and chitosan) that are
generally recognized as safe (GRAS) by the U.S. Food and Drug
Administration.
MATERIALS AND METHODS
Chemicals and cell culturemedia.Chemical reagentswere obtained from
Sigma-Aldrich (St. Louis, MO), unless otherwise noted. RPMI 1640 me-
dium was purchased from Invitrogen Life Technologies (Carlsbad, CA).
R10 medium, made of RPMI 1640 containing 10% fetal bovine serum
(FBS) (Tissue Culture Biologicals, Tulare, CA), 100 U/ml penicillin, 100
g/ml streptomycin, 2 mM L-glutamine (Invitrogen), and 55 M2-mer-
captoethanol (2-ME) (Invitrogen) was also used. Chicken ovalbumin
(OVA) containing1 endotoxin unit per mg was purchased from Wor-
thington Biochemical Corporation (Lakewood, NJ). Mouse serum albu-
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min was purchased from Equitech Bio (Kerrville, TX). Cells were incu-
bated at 37°C in humidified air supplemented with 5% CO2.
Mice. Wild-type specific-pathogen-free C57BL/6 mice were pur-
chased from The Jackson Laboratory (Bar Harbor, ME) or Charles River
Laboratories (Wilmington, MA). The protocols for the mouse experi-
ments were approved by The University ofMassachusetts Medical School
Institutional Use and Care of Animals Committee.
Mouse BMDCs. Murine bone marrow-derived dendritic cells
(BMDCs)were generated by culturing bonemarrow cells for 8 days inR10
medium supplemented with granulocyte-macrophage colony-stimulat-
ing factor (GM-CSF) followed by positive selection with CD11c mag-
netic beads, as in our previous studies, with slight modification (2). In
some experiments, 5 ng/ml (final concentration) recombinant murine
GM-CSF (PeproTech, Rocky Hill, NJ) was used instead of GM-CSF con-
ditioned medium. The proliferation of BMDCs was irreversibly inhibited
by treatment with 50 g/ml mitomycin C in RPMI 1640 for 30 min at
37°C.
GP-OVA/tR, GP-OVA/AC, GP-OVA/ACC, and GP-MSA/tR. GPs
were purified from baker’s yeast using a series of chemical and organic
extractions as described previously (12). GPs containing complexed OVA
and yeast tRNA (GP-OVA/tR) or mouse serum albumin (MSA) and tR
(GP-MSA/tR)were formulated as described previously (12).GPs contain-
ing OVA trapped with alginate and calcium (GP-OVA/AC) were synthe-
sized by incubating dry GP OVA-loaded particles in a subhydrodynamic
volume of alginate (10mg/ml) and allowing the alginate to swell and enter
the GPs. Following lyophilization, the GP-OVA-alginate particles were
incubated in a subhydrodynamic volume of 18 mM CaCl2 to ionically
cross-link the alginate, trapping the OVA in a calcium alginate gel inside
the GPs. GPs containing OVA trapped with alginate-calcium-chitosan
(GP-OVA/ACC) were synthesized by incubating dry GP-OVA/AC in a
subhydrodynamic volume of chitosan (10 mg/ml in 10 mM acetic acid)
and allowing the chitosan to swell and enter the GPs. Following lyophili-
zation, the GP-OVA-alginate-calcium-chitosan particles were incubated
in a subhydrodynamic volumeof phosphate-buffered saline (PBS) to neu-
tralize the chitosan and induce its precipitation inside GPs. The OVA
loading efficiency was90% asmeasured using a fluorescent OVA tracer.
Immunizations. GP-based formulations described above were ad-
ministered to mice (6 to 12 weeks old, 4 mice per group) subcutaneously
in a 100-l volume of 0.9% saline. Unimmunized control mice received
PBS alone. The particle numbers, antigen dose, number of immuniza-
tions, and intervals used are indicated in the figure legends.
T-cell proliferation, ELISpot, and OVA-specific Ab ELISAs. The as-
says were performed as previously described (2). Briefly, the proliferation
of purified CD4 T cells stimulated with media, concanavalin A (ConA),
or OVA was measured by [3H]thymidine incorporation with mitomycin
C-treated BMDCs as antigen-presenting cells (APCs). Similarly, for the
enzyme-linked immunosorbent spot assay (ELISpot), purified CD4 T
cells,mitomycinC-treated BMDCs, and stimuli were incubated in filtered
plates coated with capture antibodies (Abs) specific for each cytokine.
Secreted cytokines were then captured in situ and incubated with labeled
cytokine detectionAbs, and spotswere developed following the enzymatic
reaction of the substrate. Enzyme-linked immunosorbent assays (ELISAs)
to detect IgG1 and IgG2c OVA-specific antibodies in immunized mouse
serum samples were performed as described previously (13). Briefly, seri-
ally diluted mouse serum samples were incubated in OVA-coated plates,
and the IgG1 and IgG2c subclass Abs from mouse serum samples were
distinguished using biotin-conjugated rat anti-mouse IgG1 and IgG2c.
Plates were then incubated with streptavidin-conjugated horseradish per-
oxidase (eBioscience) and developed with 3,3=,5,5=-tetramethylbenzidine
solution (eBioscience), and the optical density at 450 nm (OD450) was
measured. The Ab titer was defined as the dilution factor that was 2-fold
greater than the inflection point.
FACS analysis. Single-cell suspensions from combined lymph nodes
and splenocytes (red blood cells were removed) from immunized or naive
mice were left unstimulated or cultured with OVA (final concentration,
100 g/ml) for 24 to 28 h. Brefeldin A was added for the last 5 h of
incubation. The cells were collected and stained with LIVE/DEAD blue
fixable dead cell stain kit (Invitrogen), according to the manufacturer’s
protocol. Then the cells were blocked with Fc-blocking antibodies (BD
Biosciences) and stained for surface antigens (CD3 [fluorescein isothio-
cyanate {FITC}], CD4 [V500], and CD8 [V450]). After fixation and per-
meabilization using the Cytofix/Cytoperm fixation/permeabilization kit
(BD Biosciences), the cells were stained with labeled antibodies (BD Bio-
sciences) against mouse IFN- (Alexa 700) and interleukin 17A (IL-17A)
(phycoerythrin [PE]). Single-color controls for LIVE/DEAD blue were
prepared using amine reactive compensation (ArC) beads (Invitrogen)
according to the manufacturer’s protocol. Single-color controls for CD3,
CD4, CD8, IFN-, and IL-17A were prepared using CompBeads (BD
Biosciences) according to the manufacturer’s protocol. Fluorescence-ac-
tivated cell sorter (FACS) data were collected using an LSR II flow cytom-
eter (BD) and analyzed using FlowJo software (Tree Star, Ashland, OR).
Briefly, the dead cells were excluded using the LIVE/DEADblue signal, the
CD4 CD8 population was selected from the CD3 population, and
finally the expression of IFN- and IL-17A on the live CD3CD4CD8
gated population was examined.
Statistics. Data were analyzed and the figures prepared using Graph-
Pad Prism software. For lymphoproliferation and ELISpot results, we per-
formed a one-way analysis of variance (ANOVA)with the Tukeymultiple
comparison for comparisons of three ormore groups; comparisons of two
groups were performed by two-tailed unpaired Student’s t test with a
Bonferroni correction applied for multiple comparisons. For antibody
titer data, nonparametric analyses were performed. Specifically, Kruskal-
Wallis analysis was performed for comparisons of three or more groups
andMann-Whitney analysis for comparisons of two groups. Significance
was defined as a P value of0.05.
RESULTS
Effect of antigen encapsulation on stimulation of immune re-
sponses. -Glucans have been exploited in experimental vaccines
for both their adjuvant and delivery properties (14, 15). To eval-
uate the relative contributions of these properties to the immuno-
genicity of GP-based vaccines, we compared the antigen-specific
responses in mice immunized with OVA complexed inside GPs
(i.e., GPs acting as both a delivery system and adjuvant) versus
OVA and GPs that were admixed (i.e., GPs acting only as an ad-
juvant). Thus, mice received either a mixture of GPs (GP-MSA/
tR) and free OVA (GPOVA) or OVA encapsulated inside GPs
(GP-OVA/tR). Only GP-OVA/tR stimulated CD4 T-cell re-
sponses, as measured by the lymphoproliferation assays (Fig. 1A)
and ELISpot (Fig. 1B). As in our previous studies (2), the Th1 and
Th17 responses greatly exceeded the Th2 response, as judged by
the number of IFN-- and IL-17A- versus IL-4-positive “spots.”
Both formulations stimulated comparable IgG1 antibody titers
(Fig. 1C), but GP-OVA/tR stimulated significantly higher levels of
IgG2c antibodies (Fig. 1D). These results suggest that although GPs
have some adjuvanticity whenmixedwith antigens, GPswith encap-
sulated antigens stimulatemuch stronger overall immune responses.
This was particularly pronounced for CD4 cellular immunity.
GP vaccines efficiently stimulate robust immune responses
over a wide range of encapsulated antigen concentrations. The
antigen-sparing properties of vaccines are important when an-
tigens are in short supply, such as might occur during an acute
outbreak. We previously used a relatively high dose of antigen
(50 g) in order to establish the potential utility of GP-based
vaccines (2). To determine the efficiency of the platform at
lower antigen doses, we loaded various amounts of OVA (0.5,
5, and 50g) into 5 107 GPs and immunized the animals with
these GP-OVA/tR formulations. Similar CD4 T-cell responses, as
Huang et al.














measured by CD4 T-cell lymphoproliferation (Fig. 2A) and
ELISpot (Fig. 2B), as well as IgG1 (Fig. 2C) antibody responses were
stimulated. The lowest dose (0.5 g) stimulated significantly lower
IgG2cantibody responses thandid thehighestdose (50g) (Fig. 2D).
These data establish that the GP vaccine platform is immunogenic
even at submicrogram antigen doses.
GPnumbers are important formounting strong immune re-
sponses. In the above-mentioned experiment,we varied the amount
FIG 1 Effect of antigen encapsulation in GPs on stimulation of immune responses. Mice were immunized three times at 2-week intervals with either control
GP-MSA (5 107 GP particles containing 50 g mouse serum albumin) plus 50 g free OVA (GPOVA) or GP-OVA/tR (GP-OVA/tR, 5 107 GP particles
containing 50 g OVA). CD4 T-cell lymphoproliferation (A), ELISpot (B), IgG1 ELISA (C), and IgG2c ELISA (D) were performed 2 weeks after the 3rd
immunization for one experiment and 4weeks after for the other. Data shown are combined results from these two independent experiments, with fourmice per
group for each experiment. *, P 0.05; **, P 0.01; ****, P 0.0001.
FIG 2 GP immunizations efficiently stimulate robust immune responses over a wide range of encapsulated antigen concentrations. Mice (four per group) were
immunized three times at 2-week intervals with 5 107 GP-OVA/tR containing various amounts of OVA (0.5, 5, or 50 g) per dose. Four weeks after the last
immunization, CD4T-cell lymphoproliferation (A), ELISpot (B), IgG1 ELISA (C), and IgG2c ELISA (D)were performed. The results are fromone experiment.
Data for the 50 g OVA group are also used in Fig. 1 (part of the GP-OVA/tR group). Similar results were obtained in an experiment in which mice were
immunized three times at 2-week intervals with 5 107 GP-OVA/tR containing 0.33 g, 3.3 g, and 33 g OVA per dose. *, P 0.05.
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of antigens but kept the numbers ofGPs per immunization constant.
In the next set of experiments, we sought to determine the critical
number of GPs needed to obtain vigorous immune responses. To do
this, we immunized sets of mice with the same GP formulations (50
g OVA per 5 107 GPs) but varied the number of GPs the mice
received.We found that only the group receiving the largest amount
of particles (5 107 GP-OVA/tR per dose, containing 50 g OVA)
stimulated robust immune responses (Fig. 3A to D). Groups receiv-
ing fewer particles (5 105 to 5 106, delivering 0.5 to 5 g OVA)
had little to no responses. By comparing the groups immunizedwith
the sameamountofOVAbutdifferentnumbersofGPs (Fig. 2and3),
it is apparent that a critical number of GPs is needed to elicit robust
immune responses.
One boost is sufficient to mount robust immune responses.
For the aforementioned immunization schemes, we gave two
boosts following the priming dose. Given that reducing the num-
ber of boosts would have obvious benefits for vaccination pro-
grams, we compared the antigen-specific responses in mice im-
munized once (prime only), twice (prime plus boost), or three
times (prime plus two boosts). We found that CD4 T-cell pro-
liferative responses and OVA-specific IgG1 and IgG2c antibodies
did not significantly differ when comparing one boost with two
boosts (Fig. 4A to C). However, immunization with only a prime
did not elicit strong immune responses.
GP vaccines stimulate long-term durable responses. Ideal
vaccines stimulate long-lasting immune responses. Therefore, we
next evaluated the durability of the responses following GP-
OVA/tR immunization (prime and two boosts). In the first set of
experiments, OVA-specific CD4 lymphoproliferation (Fig. 5A),
ELISpot (Fig. 5B), IgG1 (Fig. 5C), and IgG2c (Fig. 5D) responses
were found to be strong seven to eight months following the last
immunization.We then examined intracellular IFN- and IL-17A
FIG 3 Effect of GP number and antigen concentration on immune responses. Mice were immunized three times at 2-week intervals with the indicated number
of GP-OVA/tR (containing 50 g OVA per 5  107 particles; 5 g OVA per 5  106 particles; 0.5 g per 5  105 particles). Two or 4 weeks after the last
immunization, CD4 T-cell lymphoproliferation (A), ELISpot (B), IgG1 ELISA (C), and IgG2c ELISA (D) were performed. Data shown are combined results
from two independent experiments with 4 or 5mice per group for each experiment. Some of the data for the 5 107 GP group are also used in Fig. 1 (part of the
GP-OVA/tR group) and Fig. 2 (50 g OVA group). **, P 0.01; ***, P 0.001; ****, P 0.0001.
FIG 4 Effect of number of GP immunizations on immune responses. Mice were immunized once (prime only), twice (prime and one boost), or three
times (one prime and two boosts) with 5 107 GP-OVA/tR (containing 5g OVA per 5 107 particles) per dose. Immunizations were at 2-week intervals
for those mice that received boosts. Three weeks after the last immunization, CD4 T-cell lymphoproliferation (A), IgG1 (B), and IgG2c (C) were
performed. Data are combined results from two independently performed experiments, with four mice per group for each experiment. *, P  0.05; ***,
P  0.001; ****, P  0.0001.
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staining in CD4 T cells 18 to 20 months following the last im-
munization. We found that ex vivo OVA stimulation resulted in
increases in IFN--, IL-17A-, and dual IFN-/IL-17A-secreting
CD4T cells from immunized, but not naive, mice (Fig. 5E toH).
In addition, the OVA-specific reciprocal antibody titers from the
two mice were 163,840 and 20,480 for IgG1 and 640 and 640 for
IgG2c. These results suggest that GP vaccines might stimulate
long-term durable immune responses.
GPformulationsusingGRASmaterials. Inourprevious stud-
ies, yeast RNA was used to trap OVA in GPs because of its effec-
tiveness in complexing serum albumins inside GPs. To increase
the translational relevance of the GP platform, we tested several
GRAS materials (alginate and calcium, with or without chitosan)
as antigen-trapping agents. GP formulations containing either al-
ginate and calcium or alginate, calcium, and chitosan were com-
parable to RNA-based formulations in their capacity to induce
antigen-specific T-cell and antibody responses in mice (Fig. 6A
to D).
DISCUSSION
Our previous studies established that antigens encapsulated in
GPs stimulate potent CD4 T- and B-cell responses when given
subcutaneously to mice (2, 13). Here, we studied the properties of
the GP-based vaccine platform, particularly focusing on aspects
relevant to human development, including antigen sparing, dose
optimization, memory responses, and formulation composition.
We found that the GP platform stimulates strong and durable
immune responses to encapsulated antigens, even at submicro-
gram doses. While a single boost following the prime was suffi-
cient to mount strong responses, optimal T-cell responses re-
quired a critical number of GPs per immunization. Finally, GP
formulations that incorporated GRASmaterials as trapping com-
ponents retained immunogenicity. These findings broaden our
understanding of the GP platform and should enhance its pros-
pects for future clinical development.
GPs target antigens to APCs bearing -glucan and comple-
ment receptors (2, 13). In addition to their targeting properties,
-glucans have intrinsic adjuvant activity (14). Moreover, C5a,
which is generated as a result of complement activation by GPs
(11), has been used as an adjuvant (16). Therefore, it was of inter-
est to distinguish the antigen-targeting and intrinsic adjuvanticity
properties of GPs. Our data demonstrating that GP formulations
containing encapsulated OVA elicited superior immune re-
sponses to those of immunizations consisting of a simple mix of
GPs and OVA suggest that the antigen-targeting properties of the
GP platform are essential for optimal immunogenicity. However,
the finding that a mix of GPs and antigen still generated some
responses attests to the intrinsic adjuvant properties of GPs. In-
terestingly though, mixing GPs and OVA generated significant
antibody titers but not CD4 T-cell responses. Consistent with
our data, it has been reported that the host sees more “danger”
when antigens are codelivered with PAMPs into the same phago-
cytic compartment (17).
T-cell activation is more efficient when clusters of peptide-
major histocompatibility complex (MHC) molecules are dis-
played on the surfaces of APCs (18). All the antigens delivered to
an APC by a single antigen-laden GP should traffic to a distinct
phagolysosomal compartment. An antigen load of 0.5 g of OVA
in 5  107 GPs delivers 100,000 OVA molecules per GP. We
speculate that the capability of the GP platform to induce potent
FIG 5 Durability of responses stimulated by GP immunizations. (A to D) Mice were immunized three times at 2-week intervals with 5  107 GP-OVA/tR
containing 50g per dose. Control mice received PBS. Seven to 8months after the last immunization, CD4 T-cell lymphoproliferation (A), ELISpot (B), IgG1
ELISA (C), and IgG2c ELISA (D) were performed. Results are from two independent experiments, with a total of fourmice per GP-OVA/tR group and twomice
per control group. (E to H)Mice were left unimmunized (naive) or immunized three times at 2-week intervals with 5 107 GP-OVA/tR (containing 5g OVA
per 5 107 particles) per dose. Eighteen to 20months following the last immunization, intracellular expression of IFN- and IL-17AbyCD4T cells frommixed
lymph nodes and spleens was determined by FACS. Groups included naive mice stimulated with media (E) or OVA (F) and vaccinated mice stimulated with
media (G) or OVA (H). Data shown are representative results from two similar experiments. *, P 0.05; ****, P 0.0001.
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cellular immune responses even at submicrogram antigen doses is
due, at least in part, to preferential clustering when peptides are
derived from same compartment.
Despite the ability of GPs to target antigen to APCs, immune
responses declined when mice received5 107 GPs per immu-
nization. All the major phagocytic populations, including neutro-
phils, macrophages, and DCs express Dectin-1 and complement
receptors and are able to phagocytize GPs. Our preliminary data
(H. Huang, G. R. Ostroff, and S. M. Levitz, unpublished data)
demonstrate that only aminority of GPs are phagocytosed byDCs
at the subcutaneous injection site. As DCs are thought to be the
primary cell type that initiates adaptive immune responses, mod-
ifying the GP platform to selectively target DCs might result in
vaccines that require fewer GPs per dose. While clinical trials are
needed to determine the optimal number of GPs in the context of
human vaccination, it should be noted that the mass of 5  107
GPs is only 100 g.
Ideal vaccines provide protective immunity after a minimum
number of immunizations. Reducing the number of immuniza-
tions with GP-OVA from three doses to two did not significantly
compromise antigen-specific antibody and CD4 T-cell re-
sponses. AlthoughT-cell responses were not detected after a single
immunization with GP-OVA, modest antibody responses were
observed. While such responses might be useful for protection
against diseases that do not require high titers of antibody, future
efforts will be directed to develop formulations that elicit more
vigorous responses after only a single dose.
It is desirable that vaccination confers long-term protective
immunity. We found that following immunization with GPs, an-
tigen-specific responses prevailed for essentially the life span of the
mouse. Moreover, even 18 to 20months following the last immu-
nization, approximately 10% and 2% of the CD4 T-cell popula-
tion stained positive for intracellular IFN- and IL-17A, respec-
tively, following ex vivo stimulation with OVA. These data suggest
that long-term Th1 and Th17 memory responses are induced us-
ing the GP platform. Although there is controversy regarding the
longevity of Th17 cells, our results are consistent with a recent
study showing long-lasting Th1 and Th17memory cells following
subunit vaccination with antigens administered with the cationic
liposome adjuvant CAF01 (19). Interestingly, in both our study
and the aforementioned study, a small but distinctive population
of IFN-/IL-17A double-positive antigen-specific CD4 T cells
was detected. The development, plasticity, and functionality of
these CD4 T-cell lineages after immunization remain to be de-
fined.
Regulatory agencies have rigorous safety requirements for new
vaccines, including a requirement to test all component parts (1).
Thus, translation from preclinical testing to clinical trials and
eventual human approval is facilitated by the use of GRAS mate-
rials. As yeast RNA is not considered a GRASmaterial by the FDA,
we studied whether combinations of alginate and calcium, with
and without chitosan, three materials that are GRAS, could be
substituted for RNA to trap OVA inside GPs.We found that the
combination of alginate plus calcium was slightly inferior to
the standard yeast RNA formulation at stimulating some T-cell
responses. However, the addition of chitosan to alginate and
calcium resulted in antibody and T-cell responses similar to
those stimulated by RNA-based formulations. While chitosan
has been shown to activate the inflammasome (20), additional
studies will be needed to determine whether inflammasome
activation contributes to the enhanced immunogenicity of chi-
tosan-containing GPs.
Finally, our studies utilized responses to OVA to assess vari-
ables that affect the immunogenicity of the GP platform. It is
FIG 6 GP formulations containing GRAS materials. Mice (four per group) were immunized three times at 2-week intervals with 5 107 particles containing 5
g OVA per dose. Three methods of encapsulations were compared: yeast tRNA (tR) (GP-OVA/tR), alginate and calcium (AC) (GP-OVA/AC), and alginate,
calcium, and chitosan (ACC) (GP-OVA/ACC). Mice were euthanized 4 weeks after the 3rd immunization, following which CD4 T-cell lymphoproliferation
(A), ELISpot (B), IgG1 ELISA (C), and IgG2c ELISA (D) were performed. Results are from one experiment. Data for the tR group are also used in Fig. 2 (part of
the 5 g OVA group). Comparable results were obtained from a similarly designed experiment (mice were immunized three times at 2-week intervals with 5
107 respective GP-OVA constructs containing 3.3 g OVA per dose). *, P 0.05.
Huang et al.














appreciated that immune responses to model antigens, while in-
formative, cannot be relied upon to predict vaccine-mediated
protection. In this regard, in published (21) and unpublished
works, we have begun to study GP-based vaccines in models of
infection, with encouraging results.
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